These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38435431)

  • 21. Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective.
    Montagnana M; Benati M; Danese E
    Ann Transl Med; 2017 Jul; 5(13):276. PubMed ID: 28758102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early diagonosis of ovarian cancer: serum HE4, CA125 and ROMA model.
    Wang H; Liu P; Xu H; Dai H
    Am J Transl Res; 2021; 13(12):14141-14148. PubMed ID: 35035759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer.
    Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
    Medicine (Baltimore); 2015 Dec; 94(52):e2402. PubMed ID: 26717395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A label-free dual immunosensor for the simultaneous electrochemical determination of CA125 and HE4 biomarkers for the early diagnosis of ovarian cancer.
    Bilgi Kamaç M; Altun M; Yilmaz M; Sezgintürk MK
    Anal Bioanal Chem; 2023 Apr; 415(9):1709-1718. PubMed ID: 36719438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
    Fujiwara H; Suzuki M; Takeshima N; Takizawa K; Kimura E; Nakanishi T; Yamada K; Takano H; Sasaki H; Koyama K; Ochiai K
    Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of Sonographic Morphology Score and Tumor Markers for Detecting Postoperative Recurrent Pelvic Ovarian Carcinoma: Compared With MRI Assessment.
    Shen ZY; Shen AJ; Yang SL; Wu MF
    Ultrasound Q; 2019 Mar; 35(1):45-53. PubMed ID: 30672869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Lycke M; Kristjansdottir B; Sundfeldt K
    Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urine CA125 and HE4 for the Detection of Ovarian Cancer in Symptomatic Women.
    Barr CE; Njoku K; Owens GL; Crosbie EJ
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proofs for implementation of higher HE4 and ROMA index cut-off values in ovarian cancer preoperative stratification.
    Špacir Prskalo Z; Bulić P; Langer S; Gaće M; Puljiz M; Danolić D; Alvir I; Mamić I; Šušnjar L; Mayer L
    J Obstet Gynaecol; 2019 Feb; 39(2):195-201. PubMed ID: 30207507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Copenhagen index (CPH-I) is more favorable than CA125, HE4, and risk of ovarian malignancy algorithm (ROMA): Nomogram prediction models with clinical-ultrasonographic feature for diagnosing ovarian neoplasms.
    Song Z; Wang X; Fu J; Wang P; Chen X; Zhang D
    Front Surg; 2022; 9():1068492. PubMed ID: 36713666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum CA125 and HE4 as Biomarkers for the Detection of Endometrial Cancer and Associated High-Risk Features.
    Barr CE; Njoku K; Jones ER; Crosbie EJ
    Diagnostics (Basel); 2022 Nov; 12(11):. PubMed ID: 36428894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
    Terlikowska KM; Dobrzycka B; Witkowska AM; Mackowiak-Matejczyk B; Sledziewski TK; Kinalski M; Terlikowski SJ
    J Ovarian Res; 2016 Jul; 9(1):43. PubMed ID: 27436085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer.
    Dikmen ZG; Colak A; Dogan P; Tuncer S; Akbiyik F
    Eur J Gynaecol Oncol; 2015; 36(4):457-62. PubMed ID: 26390703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia.
    Winarto H; Laihad BJ; Nuranna L
    Asian Pac J Cancer Prev; 2014; 15(5):1949-53. PubMed ID: 24716917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of serum miR-21, HE4 and CA125 in surveillance for postoperative recurrent or metastatic ovarian cancer.
    Gong Z; Han S; Zhang C; Zhao H; Xu J; Sun X
    Pak J Med Sci; 2022; 38(4Part-II):939-945. PubMed ID: 35634597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.
    Ortiz-Muñoz B; Aznar-Oroval E; García García A; Covisa Peris A; Perez Ballestero P; Sanchez Yepes M; Garcia Lozano T; Illueca Ballester C; García Garcia E
    Tumour Biol; 2014 Jul; 35(7):7249-58. PubMed ID: 24771264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exosomal biomarkers in the differential diagnosis of ovarian tumors: the emerging roles of CA125, HE4, and C5a.
    Shi H; Liu L; Deng X; Xing X; Zhang Y; Djouda Rebecca Y; Han L
    J Ovarian Res; 2024 Jan; 17(1):4. PubMed ID: 38178252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.